Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low - Here's What Happened

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $8.15 and last traded at $8.17, with a volume of 2602714 shares traded. The stock had previously closed at $9.42.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Guggenheim reiterated a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Piper Sandler reduced their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Chardan Capital restated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 17th. Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an "outperform" rating and a $46.00 price target on the stock. Finally, Scotiabank initiated coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $47.46.

Dyne Therapeutics Stock Up 0.9 %

The company has a market capitalization of $796.37 million, a PE ratio of -1.98 and a beta of 1.21. The stock's fifty day moving average price is $11.86 and its two-hundred day moving average price is $21.34.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. On average, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now directly owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in DYN. GF Fund Management CO. LTD. purchased a new position in Dyne Therapeutics during the 4th quarter valued at about $50,000. KBC Group NV lifted its holdings in shares of Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after purchasing an additional 978 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in shares of Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after purchasing an additional 721 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Dyne Therapeutics in the 4th quarter worth approximately $205,000. Finally, GAMMA Investing LLC increased its position in Dyne Therapeutics by 837.5% during the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock valued at $251,000 after buying an additional 2,345 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.